Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Sofosbuvir plus Daclatasvir with or without ribavirin and velpatasivr/sofosbuvir with or without ribavirin in genotype 2 and 3 HCV-infected patients: An observational retrospective study

Trial Profile

Efficacy of Sofosbuvir plus Daclatasvir with or without ribavirin and velpatasivr/sofosbuvir with or without ribavirin in genotype 2 and 3 HCV-infected patients: An observational retrospective study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2018 Results published in the Journal of Hepatology
    • 19 Jul 2018 New trial record
    • 05 Jun 2018 Results presented at the Digestive Disease Week 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top